Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carter

Showing results (821-830 of 872) with videos related to

Pageof 88
Sort By:
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonistsZhonghui Lu, James J-W Duan, Haiyun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2014
Expression and prognostic impact of lncRNAs in acute myeloid leukemiaRamiro Garzon, Stefano Volinia, Dimitrios Papaioannou, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2017
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemiaDimitrios Papaioannou, Changxian Shen, Deedra Nicolet, et al.
Blood|July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.
Pageof 88

Showing results (821-830 of 872) with videos related to

Sort By:
Pageof 88
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonistsZhonghui Lu, James J-W Duan, Haiyun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2014
Expression and prognostic impact of lncRNAs in acute myeloid leukemiaRamiro Garzon, Stefano Volinia, Dimitrios Papaioannou, et al.
Journal of Medicinal Chemistry|December 28, 2020
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2Chunjian Liu, James Lin, Charles Langevine, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 24, 2017
Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemiaDimitrios Papaioannou, Changxian Shen, Deedra Nicolet, et al.
Blood|July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2Michael G Yang, Zili Xiao, Rulin Zhao, et al.
Pageof 88